ZA932763B - Mutani respiratory syncytial virus (RSV) vaccines containing same and methods of use - Google Patents

Mutani respiratory syncytial virus (RSV) vaccines containing same and methods of use

Info

Publication number
ZA932763B
ZA932763B ZA932763A ZA932763A ZA932763B ZA 932763 B ZA932763 B ZA 932763B ZA 932763 A ZA932763 A ZA 932763A ZA 932763 A ZA932763 A ZA 932763A ZA 932763 B ZA932763 B ZA 932763B
Authority
ZA
South Africa
Prior art keywords
rsv
methods
mutani
respiratory syncytial
syncytial virus
Prior art date
Application number
ZA932763A
Other languages
English (en)
Inventor
Valerie Bruce Randolph
Joan Coflan Crowley
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of ZA932763B publication Critical patent/ZA932763B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561—Methods of inactivation or attenuation
    • C12N2760/18564—Methods of inactivation or attenuation by serial passage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA932763A 1992-04-21 1993-04-20 Mutani respiratory syncytial virus (RSV) vaccines containing same and methods of use ZA932763B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87142092A 1992-04-21 1992-04-21

Publications (1)

Publication Number Publication Date
ZA932763B true ZA932763B (en) 1994-02-08

Family

ID=25357402

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA932763A ZA932763B (en) 1992-04-21 1993-04-20 Mutani respiratory syncytial virus (RSV) vaccines containing same and methods of use

Country Status (13)

Country Link
US (1) US5932222A (fr)
EP (1) EP0567100B1 (fr)
JP (1) JPH0622756A (fr)
AT (1) ATE177785T1 (fr)
AU (1) AU671983B2 (fr)
CA (1) CA2094464C (fr)
DE (1) DE69323921T2 (fr)
DK (1) DK0567100T3 (fr)
ES (1) ES2130189T3 (fr)
GR (1) GR3029716T3 (fr)
NZ (1) NZ247444A (fr)
TW (1) TW275632B (fr)
ZA (1) ZA932763B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2142817C1 (ru) * 1993-08-06 1999-12-20 Коннот Лабораториз Лимитед Инактивированные вакцины респираторно-синцитиального вируса
PT784486E (pt) * 1994-10-05 2006-07-31 Univ Vanderbilt Inerleucina-12 como um adjuvante para vacinas contra paramyxoviridae
US7846455B2 (en) * 1996-07-15 2010-12-07 The United States Of America As Represented By The Department Of Health And Human Services Attenuated chimeric respiratory syncytial virus
US6689367B1 (en) * 1995-09-27 2004-02-10 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
US6015664A (en) * 1995-11-03 2000-01-18 Mcw Research Foundation Multiplex PCR assay using unequal primer concentrations to detect HPIV 1,2,3 and RSV A,B and influenza virus A, B
US6077514A (en) * 1996-04-04 2000-06-20 The Regents Of The University Of Michigan Attenuated respiratory syncytial virus
EP0917592A4 (fr) * 1996-04-04 2002-04-24 Univ Michigan Virus respiratoire syncytial attenue
KR20000048628A (ko) * 1996-09-27 2000-07-25 윌리암 에이취 캘넌, 에곤 이 버그 모노네가비랄레스 목의 바이러스에서 감쇠를 책임지는 3' 게놈프로모터 영역 및 폴리머라제 유전자 돌연변이
DE19729161A1 (de) 1997-07-08 1999-01-14 Basf Ag Thermisch härtbare, wässrige Zusammensetzungen
CN1273603A (zh) * 1997-09-19 2000-11-15 美国氰胺公司 减毒的呼吸道合胞病毒
JP2002507408A (ja) * 1998-03-26 2002-03-12 アメリカン・サイアナミド・カンパニー 麻疹ウイルスもしくはヒト呼吸合胞体ウイルスサブグループｂの弱毒化の原因である突然変異
CA2418939A1 (fr) * 2000-08-07 2002-02-14 Aventis Pasteur Limited Stabilisation d'immunogenes derives de paramyxovirus
EP1701738B1 (fr) * 2003-12-17 2015-03-11 Wyeth LLC Méthode pour la production de compositions de VRS stables au stockage
GB201202091D0 (en) 2012-02-07 2012-03-21 Renishaw Ireland Ltd Drug delivery apparatus
GB201202093D0 (en) * 2012-02-07 2012-03-21 Renishaw Ireland Ltd Drug storage apparatus
CA3178538A1 (fr) * 2020-05-13 2021-11-18 Peter L. Collins Vaccin contre le vrs portant une ou plusieurs mutations du gene p
CN112501134B (zh) * 2020-12-09 2023-01-20 贵州医科大学附属医院 一种人呼吸道合胞病毒毒株及其应用
CN113462656B (zh) * 2021-03-24 2022-09-30 兰州生物制品研究所有限责任公司 一种人三型副流感病毒冷适应温度敏感株及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149650A (en) * 1986-01-14 1992-09-22 University Of North Carolina At Chapel Hill Vaccines for human respiratory virus
WO1987004185A1 (fr) * 1986-01-14 1987-07-16 University Of North Carolina Vaccins contre le virus respiratoire humain
US5223254A (en) * 1987-09-29 1993-06-29 Praxis Biologics, Inc. Respiratory syncytial virus: vaccines
WO1989004835A1 (fr) * 1987-11-20 1989-06-01 The Upjohn Company VACCIN CONTRE LE VIRUS SYNCYTIAL RESPIRATOIRE HUMAIN DERIVE DE LA PROTEINE 1A (9,5 kD)
KR0137963B1 (ko) * 1987-12-23 1998-04-30 로버트 에이. 아미테이지 인간의 호흡기 합포체성 바이러스에 대한 당단백질 면역 단편을 함유하는 키메라(chimeric) 당단백질
IL105456A (en) * 1992-04-21 1996-12-05 American Home Prod Vaccines of attenuated respiratory syncytial virus

Also Published As

Publication number Publication date
US5932222A (en) 1999-08-03
ES2130189T3 (es) 1999-07-01
DK0567100T3 (da) 1999-09-27
GR3029716T3 (en) 1999-06-30
TW275632B (fr) 1996-05-11
DE69323921T2 (de) 1999-08-26
EP0567100B1 (fr) 1999-03-17
AU3705793A (en) 1993-10-28
CA2094464C (fr) 2005-08-23
NZ247444A (en) 1994-12-22
JPH0622756A (ja) 1994-02-01
CA2094464A1 (fr) 1993-10-22
DE69323921D1 (de) 1999-04-22
EP0567100A1 (fr) 1993-10-27
ATE177785T1 (de) 1999-04-15
AU671983B2 (en) 1996-09-19

Similar Documents

Publication Publication Date Title
ZA932763B (en) Mutani respiratory syncytial virus (RSV) vaccines containing same and methods of use
EP1398379A3 (fr) Composés pour l'immunothérapie et le diagnostic de la tuberculose
WO1998053075A3 (fr) Composes pour l'immunotherapie et pour le diagnostic de la tuberculose et leur utilisation
WO1998016646A3 (fr) Composes et methodes utilises pour l'immunotherapie et le diagnostic de la tuberculose
EP1071451A4 (fr) Composes et methodes pour l'immunotherapie et le diagnostic de la tuberculose
DE3856141D1 (en) Respiratorisches syncytiales virus, impstoffe
DE69818707D1 (de) Chitosan und influenza-antigen(e) enthaltende impfstoff-zubereitungen zur verabreichung durch eine mukosa
OA09743A (en) "procedure and apparatus for the purification of air, flue gases or equivalent".
FR2718452B1 (fr) Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
MA22842A1 (fr) Procede de preparation de compositions de vaccin.
CA2022420A1 (fr) Vaccin contre escherichia coli
PL301576A1 (en) Novel hiv protease inhibitors, method of obtaining such inhibitors, pharmaceutical preparation and novel initial compounds
NL300336I2 (nl) Vaccin tegen de bof dat een jeryl-lynn virusstam bevat
WO1992006113A3 (fr) DERIVES DE gp160 ET VACCINS A BASE DE gp160 OU D'UN DE SES DERIVES, CONTENANT UN ADJUVANT
MA22938A1 (fr) Procede d'obtention d'un vaccin antirabique avirulent.
HU9801705D0 (en) Streptococcus equi vaccine
AU653861B2 (en) Respiratory disease vaccine for cats
ITRM920074A1 (it) Procedimento per la preparazione di vaccini, e vaccini cosi' ottenibili.
WO2000046242A3 (fr) PROTEINE DE 19 KILODALTONS PRODUITE PAR LA BACTERIE $i(HELICOBACTER PYLORI)
AU8177494A (en) Process for preparing clear sera which are stable over a long period